Agios Pharmaceuticals, Inc. (AGIO) stock
AGIONasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 12/307% above fair value
$29.68−0.21 (-0.70%)
Close on Nov 18, 2026Market cap $1.77BP/E –Yield –
Agios Pharmaceuticals operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
Agios Pharmaceuticals's operating cash flow for the twelve months ending Jun 30, 2026 was -$360.60M. For fiscal 2025 it was -$372.98M. The highest annual figure on record is $38.56M in fiscal 2016.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$372.98M | – |
| FY2024 | Dec 31, 2024 | -$389.84M | – |
| FY2023 | Dec 31, 2023 | -$296.06M | – |
| FY2022 | Dec 31, 2022 | -$309.48M | – |
| FY2021 | Dec 31, 2021 | -$407.32M | – |
| FY2020 | Dec 31, 2020 | -$290.76M | – |
| FY2019 | Dec 31, 2019 | -$370.62M | – |
| FY2018 | Dec 31, 2018 | -$304.42M | – |
| FY2017 | Dec 31, 2017 | -$285.23M | -839.7% |
| FY2016 | Dec 31, 2016 | $38.56M | – |
| FY2015 | Dec 31, 2015 | -$76.95M | – |
| FY2014 | Dec 31, 2014 | -$59.35M | – |
| FY2013 | Dec 31, 2013 | -$56.40M | – |
| FY2012 | Dec 31, 2012 | -$49.55M | – |
| FY2011 | Dec 31, 2011 | -$15.22M | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$57.31M | – |
| Q1 FY2026 | Mar 31, 2026 | -$118.92M | – |
| Q4 FY2025 | Dec 31, 2025 | -$96.21M | – |
| Q3 FY2025 | Sep 30, 2025 | -$88.15M | – |
| Q2 FY2025 | Jun 30, 2025 | -$77.12M | – |
| Q1 FY2025 | Mar 31, 2025 | -$111.49M | – |
| Q4 FY2024 | Dec 31, 2024 | -$133.17M | – |
| Q3 FY2024 | Sep 30, 2024 | -$84.22M | – |
| Q2 FY2024 | Jun 30, 2024 | -$72.59M | – |
| Q1 FY2024 | Mar 31, 2024 | -$99.87M | – |
| Q4 FY2023 | Dec 31, 2023 | -$72.49M | – |
| Q3 FY2023 | Sep 30, 2023 | -$61.64M | – |
| Q2 FY2023 | Jun 30, 2023 | -$66.75M | – |
| Q1 FY2023 | Mar 31, 2023 | -$95.18M | – |
| Q4 FY2022 | Dec 31, 2022 | -$66.16M | – |
| Q3 FY2022 | Sep 30, 2022 | -$71.35M | – |
| Q2 FY2022 | Jun 30, 2022 | -$74.23M | – |
| Q1 FY2022 | Mar 31, 2022 | -$97.74M | – |
| Q4 FY2021 | Dec 31, 2021 | -$84.09M | – |
| Q3 FY2021 | Sep 30, 2021 | -$85.18M | – |
| Q2 FY2021 | Jun 30, 2021 | -$117.29M | – |
| Q1 FY2021 | Mar 31, 2021 | -$120.75M | – |
| Q4 FY2020 | Dec 31, 2020 | -$49.40M | – |
| Q3 FY2020 | Sep 30, 2020 | -$68.21M | – |
| Q2 FY2020 | Jun 30, 2020 | -$67.80M | – |
| Q1 FY2020 | Mar 31, 2020 | -$105.36M | – |
| Q4 FY2019 | Dec 31, 2019 | -$93.61M | – |
| Q3 FY2019 | Sep 30, 2019 | -$85.59M | – |
| Q2 FY2019 | Jun 30, 2019 | -$88.15M | – |
| Q1 FY2019 | Mar 31, 2019 | -$103.27M | – |
| Q4 FY2018 | Dec 31, 2018 | -$74.19M | – |
| Q3 FY2018 | Sep 30, 2018 | -$63.84M | – |
| Q2 FY2018 | Jun 30, 2018 | -$67.40M | – |
| Q1 FY2018 | Mar 31, 2018 | -$99.00M | – |
| Q4 FY2017 | Dec 31, 2017 | -$74.45M | – |
| Q3 FY2017 | Sep 30, 2017 | -$77.72M | – |
| Q2 FY2017 | Jun 30, 2017 | -$58.99M | – |
| Q1 FY2017 | Mar 31, 2017 | -$74.07M | – |
| Q4 FY2016 | Dec 31, 2016 | -$51.22M | – |
| Q3 FY2016 | Sep 30, 2016 | -$49.03M | – |
See a number that looks wrong?